Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Kubota K, et al. Among authors: yamada k. J Clin Oncol. 2017 Nov 10;35(32):3662-3670. doi: 10.1200/JCO.2017.72.7297. Epub 2017 Sep 13. J Clin Oncol. 2017. PMID: 28902534 Clinical Trial.
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. Yoh K, et al. Among authors: yamada k. Lung Cancer. 2016 Sep;99:186-93. doi: 10.1016/j.lungcan.2016.07.019. Epub 2016 Jul 18. Lung Cancer. 2016. PMID: 27565938 Free article. Clinical Trial.
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T. Nishio M, et al. Among authors: yamada k. Cancer Sci. 2019 Mar;110(3):1012-1020. doi: 10.1111/cas.13932. Epub 2019 Feb 16. Cancer Sci. 2019. PMID: 30618179 Free PMC article. Clinical Trial.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T. Watanabe S, et al. Among authors: yamada k. Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Lung Cancer. 2019. PMID: 30797492 Free article. Clinical Trial.
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Shimokawa T, Yamada K, Tanaka H, Kubota K, Takiguchi Y, Kishi K, Saito H, Hosomi Y, Kato T, Harada D, Otani S, Kasai T, Nakamura Y, Misumi T, Yamanaka T, Okamoto H. Shimokawa T, et al. Among authors: yamada k. Cancer Med. 2021 Jan;10(2):626-633. doi: 10.1002/cam4.3641. Epub 2020 Dec 14. Cancer Med. 2021. PMID: 33319495 Free PMC article. Clinical Trial.
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Yamada K, Takayama K, Kawakami S, Saruwatari K, Morinaga R, Harada T, Aragane N, Nagata S, Kishimoto J, Nakanishi Y, Ichinose Y. Yamada K, et al. Jpn J Clin Oncol. 2013 Jun;43(6):629-35. doi: 10.1093/jjco/hyt056. Epub 2013 Apr 18. Jpn J Clin Oncol. 2013. PMID: 23599349 Clinical Trial.
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Hosomi Y, et al. Among authors: yamada k. Expert Opin Pharmacother. 2018 Jul;19(10):1049-1056. doi: 10.1080/14656566.2018.1484903. Epub 2018 Jun 21. Expert Opin Pharmacother. 2018. PMID: 29871540
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K. Yamada K, et al. Eur J Cancer. 2015 Sep;51(14):1904-10. doi: 10.1016/j.ejca.2015.06.120. Epub 2015 Jul 11. Eur J Cancer. 2015. PMID: 26174465 Clinical Trial.
A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Osaki A, Inoue K, Sakai H, Yamada K, Minato K, Ohyanagi F, Tokuda Y, Ikeda N, Kagamu H, Kubota K, Tamura T, Saeki T. Osaki A, et al. Among authors: yamada k. Jpn J Clin Oncol. 2019 Feb 1;49(2):121-129. doi: 10.1093/jjco/hyy161. Jpn J Clin Oncol. 2019. PMID: 30576544 Clinical Trial.
11,074 results
You have reached the last available page of results. Please see the User Guide for more information.